Zhitong Finance App News, Dean Diagnosis (300244.SZ) released its 2026 third quarter report. From January to September 2026, the company achieved operating income of 7.409 billion yuan, down 2.07% year on year; net profit attributable to shareholders of listed companies was 482 million yuan, up 750.28% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 418 million yuan, up 1074.80% year on year; basic earnings per share were 0.789 yuan.
During the reporting period, the company took more measures to consolidate the basic operating market, actively develop high-quality incremental customers, continuously optimize the business structure, and achieved positive results. First, operating revenue improved quarterly, and the operating recovery trend was steadily showing. The second is to deepen the strategic business layout and continue to increase the revenue share of high-value businesses; in the first three quarters, 10 new precision centers were added, bringing the total number of 120, and related business volume increased by 45% over the same period last year. Third, continue to expand high-value customers. 1,237 new customers were signed in the first three quarters, further increasing the market share. Fourth, comprehensively deepening refined management. The company promoted a 1.35 percentage point year-on-year increase in comprehensive gross margin by building an integrated regional operation system, implementing centralized supply chain management to reduce costs and increase efficiency, and continuously optimizing organizational efficiency. The net cash flow generated from operating activities in the current period was 824 million yuan, and the profit structure and profit quality continued to be consolidated.